Chondrosarcoma Market: Epidemiology, Therapies, Companies, DelveInsight | Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Val

Chondrosarcoma Companies are Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd

Chondrosarcoma emerging therapies, such as INBRX-109, TIBSOVO (ivosidenib), and others, are expected to boost the Chondrosarcoma Market in the upcoming years.

DelveInsight has launched a new report on "Chondrosarcoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Chondrosarcoma market report @ https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Chondrosarcoma Market Report:

In 2023, the chondrosarcoma market in the United States was valued at approximately USD 8.5 million, with expectations for steady growth through 2034. Across the 7MM (Seven Major Markets), there were an estimated 2,300 new chondrosarcoma cases that year.
Chondrosarcoma-a rare bone cancer-is classified into Grades I to IV, with most cases falling under Grade II. Key pharmaceutical players such as Epizyme, Bayer, and Eli Lilly are actively pursuing novel treatment approaches to meet ongoing clinical needs.
According to updated NCCN guidelines, ivosidenib is now recommended for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma. Additionally, ESMO's 2021 guidelines suggest trabectedin as a potential option for mesenchymal chondrosarcoma.
In 2023, the United States reported the highest number of chondrosarcoma cases among the 7MM countries. Conventional chondrosarcoma accounted for approximately 80% of all diagnosed cases, based on analysis.
In 2023, the chondrosarcoma market in the United States was valued at around USD 8.5 million and is expected to grow steadily over the forecast period (2024-2034). Among the EU4 nations, France held the largest share of the chondrosarcoma market, whereas Spain had the smallest.
INBRX-109 is a tetravalent DR5 agonist antibody designed to induce tumor-biased cell death. In 2021, the FDA granted both Fast Track and Orphan Drug Designations to INBRX-109 for the treatment of unresectable or metastatic conventional chondrosarcoma. Phase 1 trials have shown promising results, with disease control observed in 11 out of 12 evaluable patients and tumor burden reduction in 8 patients. Following a partial clinical hold due to liver toxicity concerns, the FDA lifted the hold after Inhibrx amended the study protocols to exclude at-risk patients. ​
Key Chondrosarcoma companies such as Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd, and others are evaluating new drugs for Chondrosarcoma to improve the treatment landscape.
Promising Chondrosarcoma therapies include INBRX-109, TIBSOVO (ivosidenib), and others.

Chondrosarcoma Overview

Chondrosarcoma refers to a group of cartilage-producing tumors that can range from locally aggressive to malignant, with varied appearances and clinical behavior. These tumors typically develop in bones formed through endochondral ossification and represent the most frequent bone sarcoma in individuals over 20 years old. They most often affect people in their 40s to 60s, commonly occurring in the pelvis, followed by the femur, humerus, and ribs. Histological grading of the tumor is the most important factor in determining prognosis.

Chondrosarcoma Market Outlook

The current approach to managing chondrosarcoma is based on tumor type, grade, and location, with histologic grading (I-III) being the strongest indicator of clinical behavior. Surgery remains the cornerstone of treatment, as chondrosarcoma is largely unresponsive to radiotherapy and chemotherapy. Surgical options include curettage, radical resection, and amputation, tailored according to tumor size, location, and malignancy level.

Estimating revenue from systemic therapies is challenging, as conventional chondrosarcoma typically shows resistance to chemotherapy. This resistance is attributed to factors such as slow tumor growth, P-glycoprotein expression (leading to doxorubicin resistance), high levels of anti-apoptotic proteins (like BCL-2), and poor vascularity limiting drug delivery. Due to the rarity of the disease, conducting randomized clinical trials is also difficult. While drugs like cisplatin and doxorubicin (borrowed from osteosarcoma/Ewing sarcoma protocols) are used, results have been limited. Other agents such as gemcitabine, ifosfamide, dasatinib, and pazopanib have shown minimal success in aggressive or metastatic cases.

Pharmaceutical companies like Inhibrx and Servier are actively investigating new treatments, with candidates in various stages of clinical development.

Discover how the Chondrosarcoma market is rising in the coming years @ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chondrosarcoma Emerging Drugs
INBRX-109: Inhibrx
TIBSOVO (ivosidenib): Servier

Scope of the Chondrosarcoma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chondrosarcoma Companies: Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd, and others
Key Chondrosarcoma Therapies: INBRX-109, TIBSOVO (ivosidenib), and others
Chondrosarcoma Therapeutic Assessment: Chondrosarcoma current marketed and Chondrosarcoma emerging therapies
Chondrosarcoma Market Dynamics: Chondrosarcoma market drivers and Chondrosarcoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Chondrosarcoma Unmet Needs, KOL's views, Analyst's views, Chondrosarcoma Market Access and Reimbursement

To know what's more in our Chondrosarcoma report, visit https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Chondrosarcoma Market Report:
Chondrosarcoma market report covers a descriptive overview and comprehensive insight of the Chondrosarcoma Epidemiology and Chondrosarcoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Chondrosarcoma market report provides insights into the current and emerging therapies.
The Chondrosarcoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Chondrosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chondrosarcoma market.

Got queries? Click here to know more about the Chondrosarcoma market Landscape https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Chondrosarcoma Patient Share (%) Overview at a Glance
5. Chondrosarcoma Market Overview at a Glance
6. Chondrosarcoma Disease Background and Overview
7. Chondrosarcoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Chondrosarcoma
9. Chondrosarcoma Current Treatment and Medical Practices
10. Unmet Needs
11. Chondrosarcoma Emerging Therapies
12. Chondrosarcoma Market Outlook
13. Country-Wise Chondrosarcoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Chondrosarcoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Chondrosarcoma Market Outlook 2034 https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Chondrosarcoma Pipeline Insights, DelveInsight

"Chondrosarcoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chondrosarcoma market. A detailed picture of the Chondrosarcoma pipeline landscape is provided, which includes the disease overview and Chondrosarcoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.